Harmony Biosciences Holdings, Inc. Common Stock (HRMY) Stock Price

HRMYStock

$37.95+46.24%52W

Market Cap$2.21B

P/E13.93x

PEG Ratio—

Div yield—

Beta0.99

HRMY Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)19.66%

Price vs S&P 500 (4W)-8.53%

VGM Score74.29

P/E Ratio (Annual)13.93x

P/CF (Annual)6.35x

Book Value / Share (Quarterly)$17.19

P/TBV (Annual)2.76x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)25.64%

Cash Flow / Share (Quarterly)$5.78

Price vs S&P 500 (YTD)-10.51%

Gross Margin (TTM)75.42%

Net Profit Margin (TTM)18.88%

EPS (TTM)$3.09

10-Day Avg Trading Volume0.85M

EPS Excl Extra (TTM)$3.09

Revenue Growth (5Y)40.31%

EPS (Annual)$2.71

ROI (Annual)15.35%

Gross Margin (Annual)77.16%

Net Profit Margin (5Y Avg)22.71%

Cash / Share (Quarterly)$11.49

P/E Basic Excl Extra (TTM)12.19x

Revenue Growth QoQ (YoY)30.32%

P/E Normalized (Annual)13.93x

ROA (Last FY)12.48%

Revenue Growth TTM (YoY)24.25%

EBITD / Share (TTM)$4.35

ROE (5Y Avg)26.30%

Operating Margin (TTM)24.03%

Cash Flow / Share (Annual)$5.69

P/B Ratio2.21x

P/B Ratio (Quarterly)2.11x

Net Income / Employee (Annual)$541,600

EV / Revenue (TTM)1.89x

Net Interest Coverage (TTM)20.21x

ROA (TTM)14.15%

EPS Growth QoQ (YoY)88.57%

EV / EBITDA (TTM)7.13x

EPS Incl Extra (Annual)$2.71

Current Ratio (Annual)3.60x

Quick Ratio (Quarterly)3.37x

3-Month Avg Trading Volume0.89M

52-Week Price Return46.24%

EV / Free Cash Flow (Annual)5.52x

P/E Incl Extra (TTM)12.19x

Revenue / Employee (TTM)$3,276,100

Tangible BV / Share (Quarterly)$15.86

P/S Ratio (Annual)2.54x

Asset Turnover (Annual)0.68x

52-Week High$43.49

Operating Margin (5Y Avg)25.91%

EPS Excl Extra (Annual)$2.71

CapEx CAGR (5Y)-56.63%

26-Week Price Return29.57%

Quick Ratio (Annual)3.51x

13-Week Price Return12.38%

Total Debt / Equity (Annual)0.19x

Current Ratio (Quarterly)3.48x

Enterprise Value$1.81B

Revenue / Share Growth (5Y)39.51%

Asset Turnover (TTM)0.75x

Book Value / Share Growth (5Y)54.57%

Revenue / Employee (Annual)$2,964,000

Inventory Turnover (Annual)31.60x

Pretax Margin (Annual)24.76%

Cash / Share (Annual)$13.43

3-Month Return Std Dev40.30%

Gross Margin (5Y Avg)79.43%

Net Income / Employee (TTM)$618,700

EBITDA Interim CAGR (5Y)32.42%

ROE (Last FY)18.24%

Net Interest Coverage (Annual)29.83x

EPS Basic Excl Extra (Annual)$2.71

P/FCF (TTM)6.58x

Receivables Turnover (TTM)9.41x

EV / Free Cash Flow (TTM)5.41x

Total Debt / Equity (Quarterly)0.15x

EPS Incl Extra (TTM)$3.09

Receivables Turnover (Annual)9.66x

ROI (TTM)17.02%

P/S Ratio (TTM)2.30x

Pretax Margin (5Y Avg)23.51%

Revenue / Share (Annual)$14.83

Tangible BV / Share (Annual)$13.53

Forward P/E9.68x

Price vs S&P 500 (52W)30.71%

P/E Ratio (TTM)12.19x

EPS Growth TTM (YoY)-0.38%

Year-to-Date Return1.42%

5-Day Price Return-0.73%

EPS Normalized (Annual)$2.71

ROA (5Y Avg)15.57%

Net Profit Margin (Annual)18.27%

Month-to-Date Return-3.34%

Cash Flow / Share (TTM)$2.87

EBITD / Share (Annual)$3.97

EPS Growth (3Y)-3.01%

Operating Margin (Annual)24.00%

LT Debt / Equity (Annual)0.17x

P/CF (TTM)6.22x

ROI (5Y Avg)18.38%

P/E Excl Extra (TTM)12.19x

LT Debt / Equity (Quarterly)0.13x

EPS Basic Excl Extra (TTM)$3.09

P/TBV (Quarterly)2.29x

P/B Ratio (Annual)2.48x

Inventory Turnover (TTM)37.87x

Pretax Margin (TTM)25.13%

Book Value / Share (Annual)$15.07

Price vs S&P 500 (13W)9.69%

Beta0.99x

P/FCF (Annual)6.72x

Revenue / Share (TTM)$16.34

ROE (TTM)20.06%

52-Week Low$25.52

vGradeB

gGradeB

mGradeA

vgmGradeB

HRMY Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 4, 2026	$1.15	$1.50	+30.63%(+$0.35)
Q1 2026	May 7, 2026	$0.93	$0.79	-15.94%(-$0.15)
Q4 2025	Feb 24, 2026	$1.07	$0.57	-46.48%(-$0.50)
Q3 2025	Nov 4, 2025	$0.86	$1.08	+25.39%(+$0.22)
Q2 2025	Aug 5, 2025	$0.96	$0.92	-3.68%(-$0.04)

HRMY Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

3.76

3.81

3.88

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
HRMYHarmony Biosciences Holdings, Inc. Common Stock	B	B	A	2.3x	24.3%	75.4%	—	$37.95
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78

About Harmony Biosciences Holdings, Inc. Common Stock

Harmony Biosciences is a pharmaceutical company commercializing therapies for rare neurological diseases with unmet medical needs. Its approved product WAKIX (pitolisant) treats cataplexy in narcolepsy patients through a novel H3 receptor mechanism. The company has multiple pipeline candidates targeting additional rare neurological conditions, positioning it in a specialized and underserved market segment.

HRMY Next Earnings Report

Report dateNov 3, 2026

QuarterQ3 2026

Report timeBMO

EPS estimate$1.47

Revenue estimate$274.25M

Also reporting on Nov 3, 2026

Scheduled date with consensus estimates — both can change before the company reports.

Earnings calendar for November 2026

HRMY Insider Transactions

SellSep 8, 2026
BUDUR KUMAR
Officer
Shares: 33,954Value: $1.45M

Open-market buys and sells filed with the SEC over the last 90 days. Grants, gifts and option exercises are excluded.

All insider transactions for September 2026

Companies in Related Industries

NGVTIngevity CorporationChemicals
ADMAADMA Biologics, Inc.Biological Products
IOSPInnospec Inc.Chemicals
ROGRogers CorporationPlastics & Resins
CLDXCelldex Therapeutics, IncIn Vitro Diagnostics
VCELVericel CorporationBiological Products
BCRXBioCryst Pharmaceuticals IncBiological Products
MTXMinerals Technologies IncIndustrial Chemicals

Same SIC sector, outside this company's own industry.

Analyst Sentiment

3.9

Buy

Consensus rating

52-Week Range

Low$25.52

High$43.49